

**I. AMENDMENTS**

**In the Specification:**

Please amend the specification as follows:

a<sub>1</sub>  
On page 52, line 6, after "was derived." please add --Further, three ESTs corresponding to portions of the consensus sequence (described in related application, U.S. Serial No. 08/828,845, incorporated by reference herein) were identified: clone 1430502 (SEQ ID NO 23); clone 2513529 (SEQ ID NO 24) and clone 958984 (SEQ ID NO 25).--

**In the Claims:**

Please amend claim 1 as follows:

a<sub>2</sub>  
1. (Amended) A purified polynucleotide [or fragment thereof derived from a CS197 gene, wherein said] consisting of a polynucleotide [is capable of selectively hybridizing to the nucleic acid of said CS197 gene and has at least 50% identity to a sequence] selected from the group consisting of SEQUENCE ID NO 1, SEQUENCE ID NO 2, [and fragments or complements thereof; or at least 80% identity with a sequence selected from the group consisting of] SEQUENCE ID NO [4] 23, SEQUENCE ID NO [5] 24, SEQUENCE ID NO 25, and complements thereof.

Please cancel claims 4, 5, 6, 11, 12, 15, 17 and 18, without prejudice or disclaimer.

Please add new claims 19 - 27 as follows:

a<sub>3</sub>  
--19. (New) A method of detecting the presence of a target polynucleotide indicative of gastro-intestinal (GI) tract tissue disease in a test sample, comprising:  
(a) contacting said test sample with at least one reagent polynucleotide comprising at least about 10 nucleotides that (i) specifically binds, and (ii) has at least